Skip to content
DataLookout
Menu

NCT07910435

Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Positron emission tomography complete response (CR) rate
Timeframe: After 17 cycles of induction therapy (cycle length = 21 days)

Secondary (6)

Progression-free survival
Event-free survival
Overall survival
Duration of response among patients who achieve CR or partial response (PR)
Duration of complete response among patients who achieve CR
Show 1 moreShow less
Incidence of adverse events

Arms and interventions

Treatment (polatuzumab vedotin, mosunetuzumab, acalabrutinib)Experimental

INDUCTION: Patients receive polatuzumab vedotin IV over 30-90 minutes on day 1 of cycles 1-6, mosunetuzumab SC on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2-17, and acalabrutinib PO BID on days 1-21 of cycles 1-17. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve less than PR discontinue study. Standard risk patients who achieve CR proceed to surveillance. Responding high-risk patients and responding standard risk patients who fail to achieve CR proceed to maintenance. MAINTENANCE: Patients receive mosunetuzumab SC on day 1 of each cycle and acalabrutinib PO BID on days 1-56 of each cycle. Cycles repeat every 56 days for up to 12 cycles (cycles 18-29) in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples, FDG PET/CT, and core biopsy (optional) throughout the trial and undergo BMA and BMB at screening (optional) and on study.

Drugs: Polatuzumab Vedotin, Acalabrutinib

Biologicals: Mosunetuzumab

Procedures: Bone Marrow Biopsy, Core Biopsy, FDG-Positron Emission Tomography and Computed Tomography Scan, Neurologic Examination, Biospecimen Collection, Bone Marrow Aspiration

Other: Patient Observation

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States